Figure 7.

Effects of combinations of various targeted drugs on proliferation of IL-4-exposed NI-1 and C2 cells. NI-1 (A) and C2 cells (B) were incubated in various concentrations of brentuximab vedotin (⨉), masitinib (○), or PKC412 (△) alone (as single drug) or in various drug combinations (■) (at fixed ratio) at 37 °C for 96 h. Then, uptake of ³H-thymidine was determined. Results are expressed as percent of control (co) and represent the mean ± SD of triplicates from one typical experiment. (C) NI-1 cells were incubated with recombinant canine IL-4 (200 ng mL⁻¹) or control medium for 48 h. Then, cells were treated with various drug combinations at fixed ratio [brentuximab vedotin (BV) + masitinib or brentuximab vedotin (BV) + PKC412] in the presence or absence of IL-4 for 96 h. Thereafter, ³H-thymidine uptake was measured. Results are expressed as percent of control (co) and represent the mean ± SD of triplicates from one typical experiment. Asterisk (*): P <0.05.